47 related articles for article (PubMed ID: 22075091)
1. Human papillomavirus vaccine risk and reality.
MacDonald N; Stanbrook MB; Hébert PC
CMAJ; 2008 Sep; 179(6):503, 505. PubMed ID: 18762616
[No Abstract] [Full Text] [Related]
2. ummary of Canadian Immunization Committee (CIC) Recommendations for Human Papillomavirus Immunization Programs.
Canadian Immunization Committee
Can Commun Dis Rep; 2014 Apr; 40(8):152-153. PubMed ID: 29769896
[No Abstract] [Full Text] [Related]
3. Immunization in Canada: a 6-year update.
Halperin SA; Pianosi K
J Can Chiropr Assoc; 2010 Jun; 54(2):85-91. PubMed ID: 20520752
[No Abstract] [Full Text] [Related]
4. The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better?
Sander B; Wong WW; Yeung MW; Ormanidhi O; Atkin K; Murphy J; Krahn M; Deeks SL
Vaccine; 2016 Apr; 34(16):1936-44. PubMed ID: 26892739
[TBL] [Abstract][Full Text] [Related]
5. An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands.
Luttjeboer J; Simons J; Westra T; Wilschut J; Boersma C; Postma M; van der Schans J
Infect Dis Ther; 2023 Aug; 12(8):2135-2145. PubMed ID: 37563438
[TBL] [Abstract][Full Text] [Related]
6. The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.
Calabro' GE; Carini E; Tognetto A; Giacchetta I; Bonanno E; Mariani M; Ricciardi W; de Waure C
Front Public Health; 2022; 10():786662. PubMed ID: 35359753
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of adult vaccinations: A systematic review.
Leidner AJ; Murthy N; Chesson HW; Biggerstaff M; Stoecker C; Harris AM; Acosta A; Dooling K; Bridges CB
Vaccine; 2019 Jan; 37(2):226-234. PubMed ID: 30527660
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluations of vaccines in Canada: a scoping review.
Rafferty ERS; Gagnon HL; Farag M; Waldner CL
Cost Eff Resour Alloc; 2017; 15():7. PubMed ID: 28484344
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.
Gervais F; Dunton K; Jiang Y; Largeron N
BMC Public Health; 2017 Mar; 17(1):283. PubMed ID: 28351348
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of vaccines in Canada: A systematic review.
Chit A; Lee JK; Shim M; Nguyen VH; Grootendorst P; Wu J; Van Exan R; Langley JM
Hum Vaccin Immunother; 2016 May; 12(5):1257-64. PubMed ID: 26890128
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of model-based cervical screening evaluations.
Mendes D; Bains I; Vanni T; Jit M
BMC Cancer; 2015 May; 15():334. PubMed ID: 25924871
[TBL] [Abstract][Full Text] [Related]
13. Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study.
Orlando G; Fasolo M; Mazza F; Ricci E; Esposito S; Frati E; Zuccotti GV; Cetin I; Gramegna M; Rizzardini G; Tanzi E;
Hum Vaccin Immunother; 2014; 10(4):986-94. PubMed ID: 24423757
[TBL] [Abstract][Full Text] [Related]
14. Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.
Kawai K; de Araujo GT; Fonseca M; Pillsbury M; Singhal PK
BMC Infect Dis; 2012 Oct; 12():250. PubMed ID: 23046886
[TBL] [Abstract][Full Text] [Related]
15. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada.
Tully SP; Anonychuk AM; Sanchez DM; Galvani AP; Bauch CT
Vaccine; 2012 Jan; 30(2):425-35. PubMed ID: 22075091
[TBL] [Abstract][Full Text] [Related]
16. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
17. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
19. Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
de Peuter MA; Littlewood KJ; Annemans L; Largeron N; Quilici S
Expert Rev Vaccines; 2010 Oct; 9(10):1187-201. PubMed ID: 20923269
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
